Day: 2025年7月17日

TOKYO, July 17, 2025 - (JCN Newswire via SeaPRwire.com) - Anime Tokyo Station, an exhibition center for Japanese anime operated by the Tokyo Metropolitan Government and the Association of Japanese Animations, has welcomed 187,602 visitors from Japan and overseas (as of June 29, 2025) as a facility that promotes the appeal of Japanese anime to the world under the motto “Making ANIME more interesting, Bringing ANIME far into the future.”This time, Anime Tokyo Station will be holding “Summer Festival at Anime Tokyo Station,” featuring various special events during summer vacation.As one of the events for Summer Festival at Anime Tokyo Station, we are pleased to announce the “TOKIO Exciting Anime Workshop.”The TOKIO Exciting Anime Workshop is an anime production workshop for elementary and junior high school students to be held over two days on August 23 and 24. In this workshop, participants will learn about stop-motion animation, the mechanics of animation, sound expression, and the production process, then work together using tablets (devices) to create animations. Creating anime through communication with others stimulates both receptivity and initiative, fostering children’s awareness and growth.Information about other workshops and events for Summer Festival at Anime Tokyo Station will be announced on the official website and official social media channels, so don’t miss out!Photos from previous anime production workshops TOKIO Exciting Anime Workshop Details(1) Date & time:Session 1: August 23, 2025, 1:00 p.m. - 5:00 p.m.Session 2: August 24, 2025, 1:00 p.m. - 5:00 p.m.(2) Venue: 14F, Tokyu East 5, 2-25-5 Minami-Ikebukuro, Toshima-ku, Tokyo*This is the building where Anime Tokyo Station is located.(3) Target participants: Elementary and junior high school students(4) Languages supported: Japanese and English(5) Fee: Free(6) Contents: Create a summer adventure with anime!Join new friends and combine your ideas, imagination, and creativity to take on the challenge of making your first anime.[Instructor Profile]Mayuko MasakiAnimated Learning Facilitator. A pioneer in anime education with extensive practice in educational institutions from elementary schools to universities. Researching animation creation that serves as a bridge between society, education, environment, and the heart through connections with Denmark and the rest of the world. Recently began applications in medical care and therapy.(7) Overview of participation:- Capacity: 20 participants per session (selected via lucky draw) *Parents/guardians are welcome to accompany participants.- Entry period: [Same for Sessions 1 and 2] July 10, 2025, 10:00 a.m. - July 27, 2025, 11:59 p.m.- Entry method: Please apply using the dedicated form.For details, please visit https://animetokyo.jp/archives/events/events33/(8) Event partner: animanoiroha*Please be aware that details are subject to change without notice.*Only beverages may be brought into the venue.*Staff will take photographs for use in Anime Tokyo Station publicity and reporting materials. By participating, it is assumed that you understand and agree to these conditions.*Please follow staff guidance when participating.Venue Overview- Name: Anime Tokyo Station (also known as "Anime Tokyo")- Location: Floors B1 to 2F of Tokyu East 5 (2-25-5 Minami-Ikebukuro, Toshima-ku, Tokyo)*4 minutes on foot from the East Exit of Ikebukuro Station- Hours: 11:00 a.m. to 7:00 p.m. (last admission: 6:45 p.m. / Special exhibitions last admission: 6:30 p.m.)- Closed: Mondays* If Monday falls on a holiday, the venue will be open on Monday and closed on the following dayNew Year's holiday periodMay be closed on other daysPlease check the venue website before coming.- Admission fee: Free- Website: https://animetokyo.jp/en/- SNS:X | https://x.com/animetokyo_info (@animetokyo_info)Instagram | https://www.instagram.com/animetokyostation/ (@animetokyostation)Inquiries regarding this press releasePublic Relations Office of "Anime Tokyo Station" (Kyodo PR)Contact person: Miri YasudaE-mail: animetokyo-pr@kyodo-pr.co.jp Press release: https://www.acnnewswire.com/docs/files/20250717.pdf Copyright 2025 JCN Newswire via SeaPRwire.com.

SAN DIEGO, CA, July 16, 2025 - (ACN Newswire via SeaPRwire.com) - International Land Alliance, Inc. (OTCQB: ILAL), (“ILAL” or the “Company”), an international land investment and development firm, today announced a new planned phase at its Cabo Oasis development. With the engineering and interior roads already completed, the Company plans to begin offering this rental property product in the next 45 days.“The market for rentals in Baja is in high demand and we will be meeting that demand with this new phase,” said ILAL president Frank Ingrande. “Not only is this a natural conduit for subsequent sales but will provide recurring rental revenues in addition to management fees. We have added a new marketing team with offices in Las Vegas and Northern California to focus on the new rental and sales phases. We have worked with this team that will now be operating in Las Vegas and Northern California for over 20 years and are excited to add this new inventory to their product offering. We have already started our weekly informational dinner seminars in Las Vegas and had our first on site sales tour.”Sales continue to be strong for ILAL as the sales team reported 8 new homesite contracts signed over the weekend, including 4 contracts from newly released inventory at Cabo Oasis. With the beachfront inventory sold, the Company has released and opened for sales sites in Oasis Phase II, which comprises 200 homesites with an average price of $30,000. Four additional sales contracts were reported from Rancho Costa Verde homesites.As previously announced, the Company reported sales at Cabo Oasis of 23 beachfront lots average price entry prices of $80,000 each and 5 new homes in the contract stage. The new homes are being built on beachfront homesites adjacent to the planned 72-room condotel on the beach fronting an existing natural lagoon at Cabo Oasis. This will serve as a flagship amenity for owners at both Rancho Costa Verde and Cabo Oasis. This Sante Fe style design will be a scaled-up version of the existing boutique hotel at Rancho Costa Verde. The total construction revenue for these first five homes is projected to be in excess of $1.3M, with the first home expecting break ground in August 2025.The Company opened up sales at its Cabo Oasis, a master planned community located just eight kilometers south of Rancho Costa Verde in San Felipe, Baja California. With 500 homesites available for development, this represents over $15,000,000 in gross lot sales potential, followed by over $125,000,000 in gross potential construction revenue.About International Land Alliance, Inc.International Land Alliance, Inc. (OTCQB: ILAL) is an international land investment and development firm based in San Diego, California. As its’ core mission, the Company has embraced technology for sustainable and socially responsible solutions, in addition to using proptech and construction tech advanced applications to meet these goals. The Company is focused on acquiring attractive raw land primarily in Northern Baja California, often within driving distance from Southern California. The Company serves its shareholders by devoting considerable time and resources to seeking out the finest sites available and obtaining the necessary development permits to build a compelling portfolio of properties, which provide a diversity of investment and living options. Please visit: www.ila.company.Safe Harbor StatementThe press release may include certain statements that are not descriptions of historical facts but are forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements may include the description of our plans and objectives for future operations, assumptions underlying such plans and objectives, and other forward-looking terminology such as "may," "expects," "believes," "anticipates," "intends," "projects,” or similar terms, variations of such terms or the negative of such terms. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements made herein. Such information is based upon various assumptions made by, and expectations of, our management that were reasonable when made but may prove to be incorrect. All such assumptions are inherently subject to significant economic and competitive uncertainties and contingencies beyond our control and upon assumptions with respect to the future business decisions which are subject to change. Accordingly, there can be no assurance that actual results will meet expectations and actual results may vary (perhaps materially) from certain of the results anticipated herein.CONTACT:Amplifi PRErik BlumErik@AmplifiPR.com Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, July 16, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the drug discovery research for Lecanemab (product name: "LEQEMBI®"), a humanized anti-human soluble amyloid B (AB)protofibril monoclonal antibody indicated for early Alzheimer's disease (early AD*), which was co-developed by Eisai and BioArctic AB (Headquarters: Sweden; herein after, BioArctic), has received “The 9th Bioindustry Award” from the Japan Bioindustry Association (JBA).The Bioindustry Award, now marking its 9th year, recognizes achievements that have significantly contributed to the development of the bioindustry or are expected to contribute to its future growth. This award acknowledges that “based on the amyloid cascade hypothesis proposed in 1992, which is a leading theory for the cause and progression mechanism of Alzheimer's disease (AD), the successful development of lecanemab—designed specifically to target highly neurotoxic AB protofibrils, beginning with the Arctic mutation—represents a major breakthrough in drug discovery originating from Japan. It is expected to contribute significantly to the advancement of the biopharmaceutical industry both domestically and internationally.”AD is a progressive, fatal disease, and a global healthcare issue that greatly impacts not only the people living with the disease, but also their loved ones, care partners and society. Based on its corporate concept of "human health care (hhc)," Eisai has taken on the challenge of this difficult issue through nearly 40 years of drug discovery in the field of dementia, while spending time with patients and their families, as well as collaborating with various stakeholders including healthcare professionals, academia, patient organizations, care centers, health screening companies, and diagnostic companies to drive the development of a dementia ecosystem that aims to raise awareness and realize early diagnosis and treatment of AD. Eisai will strive to deliver LEQEMBI to more people with early AD who need it, while accelerate the building of a dementia ecosystem and continuing to create positive impact on the various issues surrounding dementia. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both Eisai and Biogen Inc. (U.S.) co-commercializing and co-promoting the product and Eisai having final decision making authority.* Collectively referred to mild cognitive impairment due to Alzheimer’s disease (AD) or mild AD dementia.Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both Eisai and Biogen Inc. (U.S.) co-commercializing and co-promoting the product and Eisai having final decision making authority.*Collectively referred to mild cognitive impairment due to Alzheimer’s disease (AD) or mild AD dementia.Theme of awarded research:Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab, for the Novel Treatment of Alzheimer's diseaseAward recipients:Teiji Kimura (Senior Group Officer and Head of Global Alzheimer's Disease Office, Eisai Co., Ltd.)Lars Lannfelt (Professor Emeritus, Uppsala University)Hiroyuki Kato (Director, Eisai Co., Ltd.)Akihiko Koyama (Officer and Head of Data Innovation Clinical Research, DHBL, Eisai Co., Ltd.,)Tomoo Ogawa (Group Officer and Head of Medical HQs, Eisai Co., Ltd.)1. About LecanemabLecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulingamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid beta (AB). Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of AB, having a primary role in the cognitive decline associated with this progressive, debilitating condition.(1) Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble AB plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells.(2) It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.(3)Lecanemab has been approved in 45 countries and regions, including Japan, the United States, China, the European Union, South Korea, and Taiwan, and been under regulatory review in 11 countries. In January 2025, the supplemental Biologics License Application (sBLA) for intravenous (IV) maintenance dosing of the treatment was approved in the U.S. After an 18 months initiation phase with once every two weeks of dosing, a transition to the maintenance dosing regimen of 10 mg/kg once every four weeks or continuing 10 mg/kg once every two weeks may be considered. Additionally, the U.S. Food and Drug Administration (FDA) accepted Eisai’s Biologics License Application (BLA) for the LEQEMBI subcutaneous auto injector for weekly maintenance dosing in January 2025 and set a PDUFA action date for August 31, 2025.Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone antiamyloid therapy.2. About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.3. About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies cocommercializing and co-promoting the product and Eisai having final decision-making authority.(1)Sehlin D, Englund H, Simu B, Karlsson M, Ingelsson M, Nikolajeff F, Lannfelt L, Pettersson FE. Large aggregatesare the major soluble AB species in AD brain fractionated with density gradient ultracentrifugation. PLoS One.2012;7(2):e32014. doi: 10.1371/journal.pone.0032014. Epub 2012 Feb 15. PMID: 22355408; PMCID:PMC3280222.(2)Amin L, Harris DA. AB receptors specifically recognize molecular features displayed by fibril ends and neurotoxicoligomers. Nat Commun. 2021;12:3451.doi:10.1038/s41467-021-23507-z(3)Ono K, Tsuji M. Protofibrils of Amyloid-B are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. Copyright 2025 JCN Newswire via SeaPRwire.com.

Retain the exterior design, while optimizing equipment and providing for faster maintenanceTwo new trains began commercial operation, with a total of 25 trains scheduled to be delivered sequentially by 2028New Trains on the Sengkang-Punggol LRT (Photo courtesy of SBS Transit LTD)TOKYO, July 16, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) has completed delivery of the first trains for a project to enhance the transport capacity of the Automated Guideway Transit (AGT) system(1) used on the Sengkang-Punggol Light Rapid Transit (SPLRT)(2) network serving the northeast area of Singapore, based on an order received jointly with MHI's regional subsidiary Mitsubishi Heavy Industries Asia Pacific Pte. Ltd. (MHI-AP) and Mitsubishi Corporation (MC) in 2022 from the Land Transport Authority (LTA) of Singapore.(3)First two new trains were delivered and began commercial operation on July 15. On the same day, LTA hosted a ceremony to commemorate the commencement of commercial operations, attended by Singapore's Deputy Prime Minister Gan Kim Yong. MHI group will plan for sequentially deliver a total of 25 trains by 2028.The new trains retain the similar exterior design as the existing trains. In addition, our married-pair trains have achieved optimization of onboard equipment such as signaling system. The driver's cab inside the vehicle is equipped with a touch panel that allows settings to be adjusted for each piece of equipment. Further, MHI responded to various requests from the operator for improvements, such as continually accumulating vehicle information during operation and utilizing this data to enhance the speed of maintenance and troubleshooting.The population of the Sengkang and Punggol areas is growing rapidly, and the number of users of the SPLRT is increasing. Expectations for this project are high among the people involved and the surrounding residents. MHI based on their track record of stable operation and after-sales service since the start of operations, will steadily implement the project.MHI Group will continue to contribute to the world through services that support the comfortable and safe transport of people and goods.(1)Automated Guideway Transit (AGT) is an electric power-driven, fully automated transportation system. A key feature is the rubber-tired carriages that provide a smooth ride with low noise. AGT is used around the world for intra-city transportation, and moving people through airports and to surrounding areas.(2)Conventionally, LRT is used as the abbreviation of "Light Rail Transit," but in the case of Singapore's Sengkang-Punggol LRT, the "R" refers to "Rapid" in accordance with that network's high-speed operation.(3)For more information on the Sengkang-Punggol LRT transport capacity enhancement project, see the following press releases.https://www.mhi.com/news/220217.htmlhttps://www.mhi.com/news/23050901.htmlAbout Mitsubishi Heavy Industries Asia Pacific Pte. Ltd. (MHI-AP)Mitsubishi Heavy Industries Asia Pacific Pte. Ltd. (MHI-AP) is a subsidiary of Mitsubishi Heavy Industries, Ltd. (MHI), one of the world's leading industrial firms. Located in Singapore, the Asia Pacific headquarters supports the growth of markets in Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, India, Australia and other parts of the region. MHI-AP builds on its global outlook and deep local insights to deliver integrated solutions to the region in urban development and infrastructure, energy and utilities, as well as logistics and transportation. As a market leader in Asia Pacific, MHI-AP provides reliable and innovative solutions that move the world forward. For more information, visit www.mhi.com/.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com Copyright 2025 JCN Newswire via SeaPRwire.com.

SINGAPORE, 16 July 2025 - (JCN Newswire via SeaPRwire.com) - Singtel and a group of leading telecommunications and tech companies today announced the signing of a contract with NEC Corporation (NEC; TSE: 6701) to build the Asia United Gateway East (AUG East) submarine cable system connecting Singapore and Japan, with Brunei, Indonesia, Malaysia, the Philippines, South Korea and Taiwan. Targeted for completion by the third quarter of 2029, the 8,900 km high-capacity cable system will support the demand for more bandwidth across this route, enhancing digital connectivity in the region.The consortium, chaired by Singtel, includes Amazon Web Services, Microsoft, ARTERIA Networks, Chunghwa Telecom, DREAMLINE, Globe Telecom, Telekom Malaysia and Unified National Networks.Mr Alan Tan, Chairperson of the Asia United Gateway Cable Management Committee and Director, Submarine Cable Planning at Singtel, stated, "With the surge in demand for high-speed connectivity and bandwidth needed for AI innovation in the region, the development of resilient, high-capacity digital infrastructure is more important than ever. We’ve initiated AUG East to connect the digital hubs of Singapore and Japan, which will strengthen and improve network diversity and reliability along an important route. This investment will play a critical role in advancing digital inclusion and catalysing economic growth across the region."Mr Tomonori Uematsu, Corporate Senior Vice President with NEC Corporation, stated, "NEC is honored to have been selected as a partner for this significant project, which will support increasingly bandwidth-intensive applications driven by technological advancements in data centers and artificial intelligence. As one of the top companies in the submarine cable business, NEC will ensure the success of this project by leveraging its extensive experience as a supplier based in Asia."Designed using the latest submarine fibre optic technologies, AUG East will feature a high-count fibre pair system delivering unprecedented bandwidth capacity, enabling support for millions of simultaneous ultra high-definition video streams. Global network traffic from AI applications and AI-enhanced applications is forecasted to exceed conventional application traffic by 2031(1), and organisations in the Asia-Pacific region now lead the world in terms of their willingness to invest in digital and generative AI technologies(2).AUG East will complement existing submarine cable systems in the region by providing additional bandwidth to meet consumers’ and businesses’ voracious demand for reliable and low-latency data access, as well as improving network diversity and cable resilience in the event of natural disasters like earthquakes.(1)AI Network Traffic Report Forecast: 2022–31 – Analysis Update, released by Omdia(2)How Generative AI is Driving Business Success in Asia, released by BCGAbout NEC CorporationNEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com. Copyright 2025 JCN Newswire via SeaPRwire.com.